@article{2611,
  keywords = {Cancer models, Lab-on-a-chip},
  author = {Eliana Steinberg and Roy Friedman and Yoel Goldstein and Nethanel Friedman and Ofer Beharier and Jonathan Abraham Demma and Gideon Zamir and Ayala Hubert and Ofra Benny},
  title = {A fully 3D-printed versatile tumor-on-a-chip allows multi-drug screening and correlation with clinical outcomes for personalized medicine},
  abstract = {Optimal clinical outcomes in cancer treatments could be achieved through the development of reliable, precise ex vivo tumor models that function as drug screening platforms for patient-targeted therapies. Microfluidic tumor-on-chip technology is emerging as a preferred tool since it enables the complex set-ups and recapitulation of the physiologically relevant physical microenvironment of tumors. In order to overcome the common hindrances encountered while using this technology, a fully 3D-printed device was developed that sustains patient-derived multicellular spheroids long enough to conduct multiple drug screening tests. This tool is both cost effective and possesses four necessary characteristics of effective microfluidic devices: transparency, biocompatibility, versatility, and sample accessibility. Compelling correlations which demonstrate a clinical proof of concept were found after testing and comparing different chemotherapies on tumor spheroids, derived from ten patients, to their clinical outcomes. This platform offers a potential solution for personalized medicine by functioning as a predictive drug-performance tool.},
  year = {2023},
  journal = {Communications Biology},
  volume = {6},
  pages = {1-14},
  month = {2023-11-13},
  issn = {2399-3642},
  url = {https://www.nature.com/articles/s42003-023-05531-5},
  doi = {10.1038/s42003-023-05531-5},
  language = {en},
}